Abstract
The hallmark of chronic myeloid leukemia (CML) is the chimeric tyrosine kinase oncogene bcr – abl. Since expression of bcr – abl mRNA frequently increases with disease progression and a duplication of the Philadelphia chromosome (harbouring the bcr – abl hybrid locus) represents the most frequent karyotypic abnormality in acute phase CML, we hypothesized that the level of BCR – ABL protein may affect the disease phenotype. Therefore, the biological effects of high and low levels of BCR – ABL expression were compared in growth factor-dependent and -independent myeloid and lymphoid cell lines. Our results demonstrated that low levels of BCR – ABL were sufficient to render these cell lines growth factor independent and tumorigenic, but higher levels were mandatory for additional protection against apoptotic stimuli. The provision of growth factor or an activated ras oncogene did not afford the same degree of protection as high levels of BCR – ABL and there were qualitative differences between the survival signals mediated by BCR – ABL and Bcl-2. These results have enabled us to establish a dose-dependent hierarchy of BCR – ABL induced biological effects, thus distinguishing the activation of pathways mediating protection from cytokine withdrawal from those protecting against other apoptotic stimuli.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cambier, N., Chopra, R., Strasser, A. et al. BCR – ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 16, 335–348 (1998). https://doi.org/10.1038/sj.onc.1201490
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201490
Keywords
This article is cited by
-
Chronic Myeloid Leukemia: Beyond BCR-ABL1
Current Hematologic Malignancy Reports (2018)
-
Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia
BMC Cancer (2014)
-
Bcr-Abl tyrosine kinase inhibitors- current status
Infectious Agents and Cancer (2013)
-
Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug
Journal of Bioenergetics and Biomembranes (2012)
-
Molecular pathways to CML stem cells
International Journal of Hematology (2010)